Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 1: GU tumours, non-prostate

LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)

Date

10 Sep 2022

Session

Proffered Paper session 1: GU tumours, non-prostate

Topics

Cancer Biology;  Clinical Research;  Translational Research;  Tumour Immunology;  Molecular Oncology;  Genetic and Genomic Testing, Counseling;  Immunotherapy

Tumour Site

Urothelial Cancers

Presenters

Thomas Powles

Citation

Annals of Oncology (2022) 33 (suppl_7): S808-S869. 10.1016/annonc/annonc1089

Authors

T.B. Powles1, S. Sridhar2, J. Bellmunt3, C.N. Sternberg4, P. Grivas5, E. Hunter6, M. Dezfouli7, M. Salter8, R. Powell9, A. Dring10, J. Green9, A. Akoulitchev11, R. Amezquita12, K. Ching13, J. Pu14, S. Deng15, A. di Pietro16, C.B. Davis17

Author affiliations

  • 1 Department Of Genitourinary Oncology, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, EC1M 5PZ - London/GB
  • 2 Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto/CA
  • 3 Department Of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston/US
  • 4 Division Of Hematology And Medical Oncology, Weill Cornell Medicine, New York/US
  • 5 Medical Oncology Dept., University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle/US
  • 6 Data Science & Bioinformatics, Oxford BioDynamics Plc, Oxford/GB
  • 7 Biology – Marker Development, Oxford BioDynamics Plc, Oxford/GB
  • 8 N/a, Oxford BioDynamics Plc, Oxford/GB
  • 9 Operations Department, Oxford BioDynamics Plc, Oxford/GB
  • 10 Microarray Department, Oxford BioDynamics Plc, Oxford/GB
  • 11 Research And Development, Oxford Biodynamics Plc, Oxford/GB
  • 12 Computational Biology, Pfizer, La Jolla/US
  • 13 Computational Biology, Pfizer, San Diego/US
  • 14 Global Biometrics & Data Management, Pfizer, Tucson/US
  • 15 Global Biometrics & Data Management, Pfizer, San Diego/US
  • 16 Gpd Immuno-oncology Department, Pfizer srl, 20152 - Milano/IT
  • 17 Translational Oncology, Pfizer, La Jolla/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract LBA74

Background

The relationship between blood biomarkers, tumor immunity, and benefit from immune checkpoint inhibitors (ICIs) is not well understood. The JAVELIN Bladder 100 trial (NCT02603432) demonstrated that avelumab 1L maintenance prolongs overall survival (OS) in pts with aUC that has not progressed with 1L chemotherapy. Blood biomarkers associated with tumor immune gene signatures in this trial may provide mechanistic insight into the development of antitumor immunity and indicate patient subpopulations that could benefit from ICIs. We used EpiSwitch analysis of PB to identify structural-functional epigenetic changes in genomic architecture, designated chromatin conformation signatures (CCSs).

Methods

PB from 496 pts in the JAVELIN Bladder 100 trial underwent EpiSwitch analysis by PCR assay of 3D genomic templates prepared from fixed intact nuclei. Tumor immune activity was scored using a gene expression signature (JAVELIN Renal 101 Immune [JR101I]). CCS association with tumor JR101I scores was determined via univariate and multivariate analyses of a training set of 80 specimens.

Results

We identified 25 CCSs from the training set. One CCS was proximal to POU2F2, a transcription factor instrumental in B cell development. Patients whose PB lacked the POU2F2 CCS had elevated tumor JR101I scores, corresponding to increased gene expression associated with tertiary lymphoid structures (TLSs). The POU2F2 CCS may therefore influence key steps in TLS formation. In patients with a median tumor mutation burden (TMB) of ≤ 7.66 non-synonymous SNVs per Mb, the avelumab+BSC vs BSC hazard ratios in the CCS-absent subpopulation was 0.56 (95% CI, 0.32–0.96; p=0.037; n=83); and in the CCS-present population was 1.2 (95% CI, 0.83–1.75; P=0.34; n=158). CCSs affecting the ability to form TLSs may influence response to avelumab at low TMB.

Conclusions

PB CCSs may be associated with TLS, tumor JR101I scores, and the degree of OS benefit. These findings support further analysis of CCSs to assess potential clinical utility.

Clinical trial identification

Editorial acknowledgement

Medical writing support was provided by Abhijith Thippeswamy of ClinicalThinking, and was funded by Pfizer as part of an alliance between Pfizer and Merck.

Legal entity responsible for the study

Pfizer, as part of an alliance between Pfizer and Merck.

Funding

Pfizer, as part of an alliance between Pfizer and Merck (CrossRef Funder ID: 10.13039/100009945).

Disclosure

T.B. Powles: Financial Interests, Personal, Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca, Ipsen, Pfizer, Novartis, Incyte, Seattle Genetics, Roche, Exelixis, MSD, Astellas Pharma, Johnson & Johnson, Eisai; Financial Interests, Personal, Other, Travel, Accommodations, Expenses: Pfizer, MSD, AstraZeneca, Roche, Ipsen; Financial Interests, Personal, Research Grant: AstraZeneca, Roche, Bristol-Myers Squibb, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Astellas Pharma, Johnson & Johnson, Eisai. S. Sridhar: Financial Interests, Personal, Advisory Role, Consulting: Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Hoffmann-La Roche, Immunomedics, Ipsen, Janssen, Merck, Pfizer, Seagen, Roche, Seattle Genetics; Financial Interests, Personal, Research Grant: Bayer, Janssen, Seagen. J. Bellmunt: Financial Interests, Personal, Other, Honoraria (Self): Pfizer, MSD, BMS, AstraZeneca, Pierre Fabre; Financial Interests, Institutional, Other, Honoraria (Institution): Takeda, MSD; Financial Interests, Personal, Advisory Board: Pfizer, MSD, BMS, AstraZeneca, Roche /Genentech, Pierre Fabre; Financial Interests, Institutional, Research Grant: Takeda, Pfizer; Financial Interests, Personal, Other, Travel/Accommodations/Expenses: Pfizer; Financial Interests, Personal, Licensing Fees: UpToDate. C. Sternberg: Financial Interests, Personal, Advisory Role: Pfizer, MSD, Merck, AstraZeneca, Astellas, Sanofi-Genzyme, Roche-Genentech, Incyte, Medscape, Janssen, UroToday, Foundation, Medicine, Immunomedics, NCI, Impact Pharmaceuticals, Bristol Myers Squibb. P. Grivas: Financial Interests, Personal, Advisory Role: AstraZeneca, Astellas Pharma, Bayer, Bristol Myers Squibb, Dyania Health, Merck, Exelixis, Foundation Medicine, Genentech/Roche, Genzyme, GlaxoSmithKline, Guardant Health, Gilead Sciences, Infinity Pharmaceuticals, Janssen, Lucence Health, Mirati Therapeutics, Pfizer, QED Therapeutics, Regeneron Pharmaceuticals, SilverBack Therapeutics, UroGen, 4D Pharma PLC, EMD Serono; Financial Interests, Institutional, Advisory Role: Seattle Genetics; Financial Interests, Institutional, Invited Speaker: Bavarian Nordic; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, Clovis Oncology, Debiopharm, Merck, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Mirati Therapeutics, Pfizer, QED Therapeutics, EMD Serono. E. Hunter: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford Biodynamics Plc. M. Dezfouli: Financial Interests, Personal, Full or part-time Employment: Oxford BioDynamics Plc. M. Salter: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford BioDynamics Plc. R. Powell: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford Biodynamics Plc. A. Dring: Financial Interests, Personal, Full or part-time Employment: Oxford BioDynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford BioDynamics Plc. J. Green: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford Biodynamics Plc. A. Akoulitchev: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Institutional, Research Grant: PACT-FNIH; Financial Interests, Personal, Stocks/Shares: Oxford Biodynamics Plc, Sibelius Natural Products Ltd. R. Amezquita: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. K. Ching: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. J. Pu: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. S. Deng: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. A. di Pietro: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer. C.B. Davis: Financial Interests, Personal, Full or part-time Employment: Pfizer.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.